Hong Yi, Liu Jiarui, Wang Weixuan, Li Hao, Kong Weijing, Li Xiaoxia, Zhang Wei, Pahlavan Sara, Tang Yi-da, Wang Xi, Wang Kai
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Center for Non-coding RNA Medicine, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Department of Education, Peking University First Hospital, Peking University, Beijing, 100035, China.
Sci China Life Sci. 2025 May 23. doi: 10.1007/s11427-024-2801-x.
Cardiovascular diseases such as myocardial infarction, heart failure, and cardiomyopathy, persist as a leading global cause of death. Current treatment options have inherent limitations, particularly in terms of cardiac regeneration due to the limited regenerative capacity of adult human hearts. The transplantation of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) has emerged as a promising and potential solution to address this challenge. This review aims to summarize the latest advancements and prospects of PSC-CM transplantation (PCT), along with the existing constraints, such as immune rejection and engraftment arrhythmias, and corresponding solutions. Encompassing a comprehensive range from fundamental research findings and preclinical experiments to ongoing clinical trials, we hope to offer insights into PCT from bench to bedside.
心血管疾病，如心肌梗死、心力衰竭和心肌病，仍然是全球主要的死亡原因。目前的治疗方案存在固有局限性，特别是在心脏再生方面，因为成年人类心脏的再生能力有限。多能干细胞衍生的心肌细胞（PSC-CMs）移植已成为应对这一挑战的一种有前景且潜在的解决方案。本综述旨在总结PSC-CM移植（PCT）的最新进展和前景，以及现有的限制因素，如免疫排斥和植入性心律失常，以及相应的解决方案。涵盖从基础研究结果和临床前实验到正在进行的临床试验的广泛内容，我们希望能为从实验室到床边的PCT提供见解。
